Middle East and Africa Neuropathic Pain Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Middle East and Africa Neuropathic Pain Market Segmentation, By Type (Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, and Transcutaneous Electrical Nerve Stimulation (Tens) Devices), Product Type (Rechargeable and Non-Rechargeable), Procedure (Invasive and Non-Invasive), Technology (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation), Modality (Stationary and Portable), Mode of Purchase (Over-the-Counter Devices and Prescription-Based Devices), Pain Type (Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain, and Coccydynia), Indication (Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, and Others), End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Third Party Distributor and Others) - Industry Trends and Forecast to 2032

Middle East and Africa Neuropathic Pain Market Size

• The Middle East and Africa neuropathic pain market size was valued at USD 488.91 million in 2024 and is expected to reach USD 988.57 million by 2032, at a CAGR of 9.2% during the forecast period
• The growth is primarily driven by the increasing prevalence of chronic diseases such as diabetes, cancer, and neurological disorders, which are major contributors to neuropathic pain in the region. Advancements in pain management technologies, including spinal cord stimulation (SCS) devices, are also facilitating the adoption of more effective treatments
• Furthermore, the rising demand for non-opioid pain management solutions, coupled with improved healthcare infrastructure and access to specialized care, is enhancing patient outcomes and driving market expansion

Middle East and Africa Neuropathic Pain Market Analysis

• Middle East and Africa (MEA) neuropathic pain market, covering conditions such as diabetic neuropathy, post-herpetic neuralgia, and chemotherapy-induced peripheral neuropathy, is becoming increasingly critical due to the rising prevalence of chronic diseases and an aging population across key countries in the region
• The escalating demand for neuropathic pain treatments is primarily fueled by advancements in pain management therapies, including spinal cord stimulation (SCS) devices, transcutaneous electrical nerve stimulation (TENS) devices, and non-opioid pharmacological interventions, aimed at improving efficacy and patient quality of life
• Saudi Arabia dominated the Middle East and Africa neuropathic pain market with the largest revenue share of 35% in 2024, supported by advanced healthcare infrastructure, increasing patient awareness, and government initiatives promoting chronic pain management, with specialized hospitals and clinics driving substantial treatment adoption
• The United Arab Emirates is expected to be the fastest-growing country in the Middle East and Africa neuropathic pain market during the forecast period, due to higher healthcare expenditure, rising adoption of novel therapies, and improved access to advanced pain management solutions
• Spinal Cord Stimulation (SCS) devices segment dominated the Middle East and Africa neuropathic pain market with a share of 43.2% in 2024, driven by their established effectiveness in managing chronic neuropathic pain and increasing adoption in hospitals, clinics, and home healthcare settings

Report Scope and Middle East and Africa Neuropathic Pain Market Segmentation 

Middle East and Africa Neuropathic Pain Market Trends

Rising Adoption of Non-Invasive and Portable Pain Management Devices

• A significant and accelerating trend in the MEA neuropathic pain market is the increasing adoption of non-invasive therapies such as TENS devices, transcranial magnetic stimulation (TMS), and portable spinal cord stimulation systems, offering patients safer and more convenient treatment options
• For instance, portable TENS devices allow patients to manage peripheral neuropathy or post-herpetic neuralgia at home, providing flexibility and reducing dependency on hospital visits while maintaining treatment effectiveness
• Integration of these devices with mobile applications enables monitoring of therapy duration, intensity, and patient compliance, enhancing treatment outcomes and personalized care in both home and clinical settings
• The trend toward portable and non-invasive devices is reshaping patient expectations, emphasizing convenience, safety, and accessibility, which is driving manufacturers to focus on innovative and user-friendly designs
• Companies such as Neurostimulation Solutions and Boston Scientific are developing AI-enabled and Bluetooth-connected neuropathic pain devices that can be adjusted remotely, offering patients improved usability and real-time therapy tracking
• Demand for portable, non-invasive, and connected neuropathic pain solutions is growing rapidly across both clinical and home healthcare settings, as patients and caregivers increasingly prioritize treatment convenience and efficacy

Middle East and Africa Neuropathic Pain Market Dynamics

Driver

Increasing Prevalence of Chronic Diseases and Aging Population

• The rising prevalence of diabetes, cancer, and post-herpetic neuralgia, coupled with an aging population in key countries such as Saudi Arabia and UAE, is a major driver for the heightened demand for neuropathic pain management solutions
• For instance, in 2024, a national diabetic neuropathy program in Saudi Arabia led to the adoption of advanced spinal cord stimulation and TENS devices in hospitals and clinics, demonstrating the impact of chronic disease burden on device adoption
• As the number of patients with neuropathic pain grows, there is an increasing need for effective treatments that can improve quality of life and reduce long-term healthcare costs across the MEA region
• Furthermore, the expansion of specialized pain management centers and rehabilitation clinics is creating an ecosystem that supports advanced therapies, increasing accessibility for patients in urban and semi-urban areas
• The availability of innovative pain management technologies, combined with rising awareness among healthcare providers and patients, is driving adoption across hospitals, clinics, and home healthcare settings
• Government initiatives, insurance coverage improvements, and awareness campaigns are enhancing patient access to advanced neuropathic pain devices, further accelerating market growth

Restraint/Challenge

High Device Costs and Limited Patient Awareness

• The relatively high cost of advanced neuropathic pain devices such as SCS and TMS systems is a significant challenge for broader adoption, particularly in price-sensitive countries within the MEA region
• For instance, portable SCS devices with AI-enabled features can cost several thousand USD, limiting accessibility for patients without insurance or government support
• Limited awareness among patients and some healthcare providers regarding the benefits of modern neuropathic pain therapies can delay adoption, especially in rural or underserved areas
• Addressing affordability issues through insurance coverage, government subsidies, and tiered pricing models is crucial for wider market penetration
• Patient and provider education on device usage, safety, and treatment efficacy is necessary to overcome hesitancy and improve acceptance of advanced neuropathic pain management solutions
• Overcoming these challenges through cost reduction, training programs, and awareness campaigns will be essential to sustaining market growth and ensuring equitable access across the MEA region

Middle East and Africa Neuropathic Pain Market Scope

The market is segmented on the basis of type, product type, procedure, technology, modality, mode of purchase, pain type, indication, end user, and distribution channel.

• By Type

On the basis of type, the neuropathic pain market is segmented into Spinal Cord Stimulation (SCS) devices, External Peripheral Nerve Stimulation, and Transcutaneous Electrical Nerve Stimulation (TENS) devices. The Spinal Cord Stimulation (SCS) devices segment dominated the market with the largest revenue share of 43.2% in 2024, driven by its effectiveness in managing chronic neuropathic pain such as diabetic neuropathy and post-herpetic neuralgia. Hospitals and clinics prefer SCS devices for patients with severe pain due to their long-term efficacy and ability to reduce opioid dependency. The devices offer customizable stimulation settings, which improve patient compliance and outcomes. Rechargeable SCS systems allow repeated use without frequent battery replacement, making them cost-effective. Integration with home-based monitoring and programmable therapy enhances their adoption. Overall, clinical preference and technological reliability reinforce the dominance of SCS devices.

The External Peripheral Nerve Stimulation segment is expected to witness the fastest growth at a CAGR of 10.2% from 2025 to 2032, fueled by rising demand for non-invasive pain relief solutions. Patients prefer these devices for peripheral neuropathy and post-traumatic neuropathy because they are safe, portable, and easy to use. Growing awareness among patients and healthcare providers is expanding adoption in home healthcare settings. Technological improvements, such as wireless connectivity and advanced electrodes, enhance usability and effectiveness. Insurance coverage in countries such as UAE and Saudi Arabia supports faster adoption. Non-invasive nature and patient-friendly design make this segment the fastest-growing.

• By Product Type

On the basis of product type, the neuropathic pain market is segmented into rechargeable and non-rechargeable devices. The Rechargeable devices segment dominated the market with a share of 58.3% in 2024, attributed to cost-effectiveness and long-term usability. Rechargeable SCS and TENS devices reduce maintenance costs and ensure uninterrupted therapy. Hospitals and clinics prefer them for continuous treatment, improving patient adherence. Advanced rechargeable devices often include mobile connectivity and programmable settings, enhancing therapeutic control. The ability to reuse devices multiple times adds economic value for healthcare providers. Patients also appreciate fewer battery replacements and consistent therapy delivery.

The Non-Rechargeable devices segment is expected to witness the fastest growth at a CAGR of 9.8% from 2025 to 2032, driven by the demand for compact, lightweight, and portable devices suitable for home use. Non-rechargeable options are more affordable and convenient for outpatient care. Increased over-the-counter availability in select countries boosts accessibility. Patients benefit from ease of use without technical support or maintenance requirements. Technological innovations in non-rechargeable devices, such as improved stimulation modes, enhance efficacy. Growing awareness of non-invasive therapies also supports rapid adoption in MEA markets.

• By Procedure

On the basis of procedure, the neuropathic pain market is segmented into invasive and non-invasive procedures. The Non-Invasive segment dominated with a market share of 61.2% in 2024, as patients prefer safer treatments with fewer complications. TENS and transcutaneous stimulation therapies are widely used for peripheral neuropathy, post-herpetic neuralgia, and post-traumatic neuropathy. Non-invasive options are suitable for home-based use, increasing accessibility and adherence. Integration with mobile apps allows monitoring of therapy intensity and duration. Hospitals and outpatient clinics benefit from reduced procedural risks and lower operational costs. Overall, safety, convenience, and patient preference reinforce dominance.

The Invasive procedures segment is expected to witness the fastest growth at a CAGR of 10.5% from 2025 to 2032, led by increasing adoption of implantable SCS devices for severe neuropathic pain. Minimally invasive surgery and improved device longevity enhance acceptance. Hospitals prefer these devices for refractory pain cases, ensuring better patient outcomes. Reimbursement and insurance coverage in key countries accelerate adoption. Implantable devices offer customizable therapy settings, improving compliance. Rising awareness among healthcare providers and patients supports rapid growth.

• By Technology

On the basis of technology, the neuropathic pain market is segmented into TENS, Transcranial Magnetic Stimulation (TMS), and Respiratory Electrical Stimulation (RES). The TENS segment dominated due to non-invasive application, ease of use, and clinical effectiveness for peripheral neuropathy and post-traumatic neuropathic pain. TENS devices are widely used in home healthcare, outpatient clinics, and hospitals. They provide portable and convenient therapy, enhancing patient adherence. Integration with smart devices and apps allows therapy monitoring and adjustments. Affordability compared to implantable devices increases adoption. Strong clinical validation and physician recommendation reinforce market leadership.

The TMS segment is expected to witness the fastest growth at a CAGR of 9.4% from 2025 to 2032, driven by rising adoption in specialized pain centers. TMS is effective for treatment-resistant neuropathic pain and nerve-related depression. Technological advancements enhance precision and patient comfort. Increasing availability in Saudi Arabia, UAE, and South Africa supports rapid uptake. Hospitals and clinics integrate TMS with other therapeutic modalities. Awareness programs for patients and providers boost adoption rates.

• By Modality

On the basis of modality, the neuropathic pain market is segmented into stationary and portable devices. The portable devices segment dominated with a share of 66.9% in 2024, driven by demand for home-based and continuous therapy. Portable devices such as TENS and wearable SCS systems allow patients to manage pain outside hospitals. Ease of use and reduced need for supervision improve adherence. Mobile connectivity and adjustable settings enhance personalized care. Hospitals and home healthcare providers prefer portable solutions for decentralized treatment. Portability and convenience make this segment dominant.

The stationary devices segment is expected to witness the fastest growth at a CAGR of 9.7% from 2025 to 2032, fueled by hospital adoption of advanced setups. Stationary devices allow continuous therapy and integration with monitoring systems. Clinics benefit from improved patient tracking and safety. Larger, more sophisticated systems provide better treatment for severe neuropathic pain. Rising hospital investment in advanced pain management technology drives growth. Specialized centers adopting stationary devices support rapid expansion.

• By Mode of Purchase

On the basis of mode of purchase, the neuropathic pain market is segmented into Over-the-Counter (OTC) devices and Prescription-Based devices. The Prescription-Based devices segment dominated with a share of 64% in 2024, as SCS, TMS, and advanced TENS systems require physician supervision. Professional oversight ensures safety, correct usage, and optimized treatment outcomes. Hospitals and clinics prefer prescription-based devices for chronic or severe neuropathic pain patients. Device programming and monitoring are often performed by healthcare providers, enhancing compliance. Insurance coverage for prescription devices supports market dominance. Regulatory frameworks in MEA countries also favor prescription-based sales.

The OTC devices segment is expected to witness the fastest growth at a CAGR of 11.1% from 2025 to 2032, driven by growing demand for portable, non-invasive solutions that can be purchased without prescription in select markets. OTC devices target mild to moderate pain conditions. Consumer awareness and affordability encourage adoption. Home healthcare and remote monitoring applications are increasing. Technological improvements enhance device safety and usability. Availability through online and retail channels boosts growth potential.

• By Pain Type

On the basis of pain type, the market is segmented into peripheral neuropathy, entrapment neuropathy, phantom limb neuropathy, trigeminal neuralgia, post-herpetic neuralgia, post-traumatic neuropathy, foot pain, and coccydynia. The Peripheral Neuropathy segment dominated due to high prevalence among diabetic and cancer patients in MEA countries. Hospitals and clinics widely adopt SCS and TENS for treatment. Continuous therapy improves patient quality of life. Clinical recommendations favor peripheral neuropathy management devices. Insurance coverage and reimbursement support adoption. Research-backed efficacy reinforces dominance.

The Trigeminal Neuralgia segment is expected to witness the fastest growth during forecast period, driven by rising awareness of minimally invasive and non-invasive therapies. Portable TENS and SCS solutions are increasingly used. Advances in nerve stimulation technology enhance safety and efficacy. Patients and clinicians are more aware of alternative therapies. Increased availability in specialized pain clinics supports adoption. Rapid adoption is supported by patient preference for convenient and effective solutions.

• By Indication

On the basis of indication, the neuropathic pain market is segmented into spinal stenosis, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and others. The Diabetic Neuropathy segment dominated due to high incidence in Saudi Arabia, UAE, Egypt, and South Africa. Chronic pain drives sustained adoption of advanced devices. Hospitals, clinics, and home healthcare providers frequently utilize SCS and TENS. Patient compliance and improved outcomes reinforce device preference. Technological integration with mobile apps enhances monitoring. Clinical guidelines support the use of these devices.

The Chemotherapy-Induced Peripheral Neuropathy segment is expected to witness the fastest growth during forecast period, fueled by increasing cancer prevalence and rising patient awareness of adjunctive pain management solutions. Non-invasive therapies are preferred. Specialized pain centers adopt these devices rapidly. Technological advances improve treatment efficacy. Home-based therapy demand supports adoption. Hospitals and clinics integrate therapies for supportive cancer care.

• By End User

On the basis of end user, the neuropathic pain market is segmented into hospitals, clinics, home healthcare, ambulatory surgical centers, and others. The Hospitals segment dominated due to established infrastructure, higher adoption of advanced SCS and TMS devices, and availability of specialized pain management units. Hospitals offer professional oversight and optimized therapy. Chronic neuropathic pain management drives frequent use. Integration with monitoring systems enhances treatment outcomes. Insurance coverage supports adoption. Hospitals serve as referral centers for complex cases.

The Home Healthcare segment is expected to witness the fastest growth during forecast period, fueled by patient preference for convenient, continuous therapy at home. Portable devices, mobile connectivity, and telemonitoring enable home use. Patients benefit from reduced hospital visits. Rising awareness of non-invasive therapy efficacy supports growth. Home healthcare adoption reduces costs for providers. Demand for self-managed therapy drives rapid uptake.

• By Distribution Channel

On the basis of distribution channel, the neuropathic pain market is segmented into direct tender, third party distributor, and others. The Direct Tender segment dominated as government hospitals and large clinics procure devices in bulk to ensure quality and reliability. Bulk purchases reduce costs and maintain consistent supply. Hospitals and clinics prefer direct procurement from manufacturers. Regulatory compliance is easier to maintain. Long-term service contracts support adoption. Device training and support are often bundled with direct sales.

The Third Party Distributor segment is expected to witness the fastest growth during forecast period, driven by expansion of private clinics, home healthcare providers, and smaller hospitals in the MEA region. Distributors improve reach to remote and underserved areas. Increased awareness among patients and providers supports growth. Faster logistics and localized support enhance adoption. Partnerships with device manufacturers expand market penetration. Smaller healthcare providers benefit from flexible purchasing options.

Middle East and Africa Neuropathic Pain Market Regional Analysis

• Saudi Arabia dominated the MEA neuropathic pain market with the largest revenue share of 35% in 2024, supported by advanced healthcare infrastructure, increasing patient awareness, and government initiatives promoting chronic pain management, with specialized hospitals and clinics driving substantial treatment adoption
• Patients and healthcare providers in the region are increasingly adopting advanced pain management solutions such as spinal cord stimulation (SCS) devices, transcutaneous electrical nerve stimulation (TENS) devices, and non-invasive therapies due to their demonstrated efficacy and safety
• The widespread adoption of these therapies is further supported by growing awareness among patients and clinicians, well-established hospitals and specialized pain clinics, and government initiatives promoting chronic disease management and patient quality of life

The Saudi Arabia Neuropathic Pain Market Insight

The Saudi Arabia neuropathic pain market captured the largest revenue share of 35% in 2024 within the MEA region, driven by the rising prevalence of diabetes, cancer, and other chronic conditions contributing to neuropathic pain. Patients and healthcare providers are increasingly adopting advanced therapies such as spinal cord stimulation (SCS) devices, transcutaneous electrical nerve stimulation (TENS) devices, and non-invasive solutions. The growing patient awareness, coupled with well-established hospitals and specialized pain clinics, supports high adoption rates. Government initiatives promoting chronic disease management and patient quality of life further drive market expansion. In addition, high healthcare expenditure, improved access to advanced medical technologies, and insurance coverage are enabling broader adoption. Overall, Saudi Arabia remains the largest and most mature neuropathic pain market in the MEA region.

United Arab Emirates Neuropathic Pain Market Insight

The UAE neuropathic pain market is poised to grow at a substantial CAGR during the forecast period, driven by increasing patient awareness, rising disposable income, and expanding access to advanced pain management therapies. The country’s modern healthcare infrastructure and specialized clinics support the adoption of SCS, TENS, and non-invasive devices. Patients increasingly prefer home-based and portable solutions, complementing hospital treatments. Insurance coverage for advanced therapies and government support programs enhances accessibility. Rising prevalence of diabetic and chemotherapy-induced neuropathic pain further fuels demand. The UAE is also emerging as a regional hub for innovative pain management technologies, contributing to sustained market growth.

South Africa Neuropathic Pain Market Insight

The South Africa neuropathic pain market is expected to expand at a considerable CAGR, driven by the prevalence of diabetic neuropathy, post-traumatic neuropathy, and chemotherapy-induced neuropathic pain. Hospitals, clinics, and home healthcare providers are increasingly adopting both invasive and non-invasive pain management solutions. Growing awareness among patients and physicians regarding the benefits of SCS, TENS, and TMS devices is boosting adoption. Economic development and increasing healthcare expenditure enable wider access to advanced therapies. The integration of portable devices for home-based treatment supports patient compliance and long-term therapy outcomes. South Africa is becoming a key regional market for innovative neuropathic pain management solutions.

Nigeria Neuropathic Pain Market Insight

The Nigeria neuropathic pain market is poised to grow at a rapid pace due to rising chronic disease prevalence, urbanization, and improvements in healthcare infrastructure. Hospitals and clinics are increasingly incorporating advanced pain management devices to treat peripheral neuropathy and post-traumatic neuropathic pain. Patients are showing growing interest in portable and non-invasive solutions for home healthcare. Government initiatives aimed at improving chronic disease management and increasing awareness support market growth. Access to cost-effective devices and partnerships with distributors enable broader reach across urban and semi-urban areas. Overall, Nigeria represents a fast-growing market opportunity in the MEA region.

Middle East and Africa Neuropathic Pain Market Share

The Middle East and Africa neuropathic pain industry is primarily led by well-established companies, including:

• Boston Scientific Corporation (U.S.)
• Abbott (U.S.)
• Nevro Corp. (U.S.)
• Pfizer Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Scilex Holding (U.S.)
• Saluda Medical Pty Ltd. (Australia)
• BTL Group of Companies (Czech Republic)
• OMRON Healthcare, Inc. (U.S.)
• Haleon Group of Companies (U.K.)
• AbbVie Inc. (U.S.)
• Lilly USA, LLC (U.S.)
• Medtronic (Ireland)
• Grünenthal (Germany)
• BioElectronics Corporation (U.S.)
• electroCore, Inc. (U.S.)
• SPR Therapeutics, Inc. (U.S.)
• Stimwave Technologies, Inc. (U.S.)
• NuroKor Ltd (U.K.)
• Neuraxpharm (Germany)

What are the Recent Developments in Middle East and Africa Neuropathic Pain Market?

• In July 2025, MIRA Pharmaceuticals announced that the FDA had cleared its Investigational New Drug (IND) application for Ketamir-2, a novel oral NMDA receptor antagonist for the treatment of neuropathic pain
• In January 2025, Artelo Biosciences announced that its investigational non-opioid drug, ART26.12, had passed a safety review and would advance into the next phase of its clinical trial. The drug, which targets a specific fatty acid binding protein (FABP), is being developed specifically for chemotherapy-induced peripheral neuropathy (CIPN), a serious side effect of cancer treatment
• In January 2025, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain. This is the first drug to be approved in a new class of non-opioid pain medicines. The drug works by targeting a pain-signaling pathway in the peripheral nervous system
• In October 2024, Neuraxpharm announced its expansion into the Middle East, submitting ublituximab for approval in Saudi Arabia and the UAE, with plans for launch in 2025. This move signifies a strategic effort to introduce advanced neuropathic pain treatments to the region, addressing the growing demand for effective pain management solutions
• In October 2024, Scilex Holding Company announced a master distributor agreement for ZTlido, a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia (PHN). ZTlido was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period

SKU-63257